James Ellison, MD
Cardiovascular Disease · Chesterfield, MONPI 1992813745
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $171,248 of the $266,705 with a category attached, or 64.2%. Boehringer Ingelheim accounts for 93.1% of it on its own, with 53 other manufacturers making up the rest. Reporting peaked in 2023 at $206,363 and has fallen 99.1% since, to $1,849 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 650 payments — averaging $410.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$248K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Boehringer Ingelheim International GmbH$4K
- Novartis$1K
- Boston Scientific$896
- Merck$834
- plus $8K from 48 others
Across 3 payments — averaging $494,415 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1.5M
- Boehringer Ingelheim International GmbH$9K
What the payments were for
- Consulting fees$83,92031%
- Speaking & faculty fees$171,24864%
- Food & beverage$11,5174%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$250
- Claria MRI$225
- WATCHMAN Access System$146
- WATCHMAN FLX$143
- Adempas$123
- FARXIGA$121
- ZYPITAMAG (pitavastatin)$105
- JARDIANCE$100
How this compares
$266,705 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 509 | $570,169 |
| EntrestoSacubitril/Valsartan | 171 | $210,787 |
| JardianceEmpagliflozin | 131 | $121,519 |
| XareltoRivaroxaban | 117 | $114,716 |
| FarxigaDapagliflozin Propanediol | 80 | $65,265 |
| Repatha SureclickEvolocumab | 45 | $40,969 |
| VerquvoVericiguat | 11 | $14,112 |
| Praluent PenAlirocumab | 15 | $12,752 |
| BrilintaTicagrelor | 16 | $10,822 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $9,186 |
| LivaloPitavastatin Calcium | 12 | $7,933 |
| Valsartan | 272 | $5,194 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 163 | $4,694 |
| Metoprolol Succinate | 383 | $4,199 |
| Rosuvastatin Calcium | 270 | $4,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $648 | $570,169509 claims |
| NovartisEntresto | $1,192 | $210,787171 claims |
| Boehringer IngelheimJardiance | $248,420 | $121,519131 claims |
| Johnson & JohnsonXarelto | $657 | $114,716117 claims |
| AstraZenecaFarxiga, Brilinta | $656 | $76,08796 claims |
| MerckVerquvo | $834 | $14,11211 claims |
| Esperion Therapeutics, Inc.Nexlizet | $314 | $9,18611 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $77 | $7,93312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Chesterfield
- Glenn DavisonChesterfield$118K
- Edward HurleyChesterfield$19K
- Keith MankowitzChesterfield$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.